2. ToxGenSolutions BV identifies a 9 miRNA peripheral profile to identify individuals at risk for late-onset Alzheimer’s Disease years in advance
14.02.2023
As part of an effort to drive the development of cutting-edge biomarkers and explore novel diagnostic technologies, ToxGenSolutions BV has identified a peripheral profile of 9 microRNAs (miRNAs) to identify individuals at risk for late-onset Alzheimer’s Disease (AD) years in advance.
The goal of the program is to diagnose late-onset Alzheimer’s Disease:
- Faster by turning the months/years it takes for the current diagnostic approach into hours.
- Cheaper by eliminating the dependence on expensive imaging.
- More accurate in the prodromal phase of the disease. Currently, nearly 50% of individuals diagnosed with mild cognitive impairment (MCI) do not develop dementia.
- Less invasive and more patient-friendly by replacing CSF sampling with a standard blood draw.
It is our pleasure to announce that the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF) will support ToxGenSolutions BV in this endeavour.